[ad_1]
Copy the link
AstraZeneca said Thursday that its COVID-19 vaccine reached 76% effectiveness in a new analysis of its flagship trial in the United States.
It’s slightly lower than that announced this week in a report that was criticized for its use of outdated information.
And US health officials this week publicly accused the drug company of using “outdated information” when it estimated the vaccine was 79 percent effective.
The latest data was based on 190 infections among more than 32,400 trial participants in the United States, Chile and Peru. Previous initial data was 141 injuries as of February 17.
“The baseline analysis is consistent with our previously published initial analysis and confirms that our COVID-19 vaccine is highly effective in adults,” said Main Pangalos, executive vice president of biomedical research and development at AstraZeneca.
AstraZeneca said it “intends to seek US approval for the emergency use of its drug in the coming weeks, and has submitted the latest data to the Data Safety Monitoring Board. , which is the independent committee overseeing the experiment. “
Today, AstraZeneca confirmed that
“The vaccine that I developed with the University of Oxford is 100% effective against severe or critical forms of the disease.”
She added that the vaccine’s effectiveness was 85% in adults over 65.
The most recent efficacy rate is 76 percent, compared to about 95 percent for the Pfizer / Biontech and Moderna vaccines.
However, the AstraZeneca vaccine is considered vital in dealing with the spread of Covid-19 around the world, not only because of the limited supply of vaccines, but also because it is easier and cheaper to transport than competition.
It has obtained conditional marketing or emergency use authorization in more than 70 countries.
The drug has faced doubts since late last year, when the company and the University of Oxford released data from previous trials that recorded different potency readings due to dose errors.
Then more than 12 countries temporarily stopped providing the vaccine this month, after reports linking it to a rare blood clot in a very small number of people, according to Reuters.
The European Union’s Medicines Control Authority said last week that “the vaccine is safe, but Europeans are still skeptical about its safety.”
[ad_2]
Source link
